Table 1.
Baseline characteristics of patient cohort
| Clinimetrics | Patients | Controls |
|---|---|---|
| Age at baseline sampling (years) | ||
| Mean±SEM | 64.67 ± 1.48 | 60.22 ± 1.73 |
| Gender | ||
| F/M | 27/33 | 19/10 |
| Ethnicity | ||
| (% non‐Caucasian) | 5% | 2% |
| Smoking | ||
| Yes/ex‐smoker/no | 13/13/34 | 14/16 |
| Site of onset | ||
| Bulbar/limb/both | 15/44/1 | – |
| Age of onset (years) | ||
| Mean± SEM | 62.43 ± 1.49 | – |
| Diagnostic latency (months) | ||
| Mean± SEM | 17.11 ± 2.91 | – |
| El‐Escorial at sampling | ||
| Definite/probable/possible/lab‐supported probable | 14/29/11/6 | – |
| ALSFRS_R score at baseline sampling | ||
| mean±SEM | 34.25 ± 1.02 | – |
| Progression rate at baseline | ||
| Mean±SEM | 0.83 ± 0.1 | – |
| Disease duration at baseline sampling (months) | ||
| Less than 1 year/2 years/3 years/more than 3 years | 18/16/11/15 | – |
ALSFRS‐r: ALS Functional Rating Scale‐revised; Progression Rate at Baseline (PRB) calculated as (48 ‐ ALSFRS_R at baseline)/time in months between onset of disease and the first visit.